-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The birth of chimeric antigen receptor T cells ( CAR-T cells) is a landmark event in the struggle between humans and tumors
.
From the emergence of the first artificially modified TCR chimeric T cells and the verification of their specific antigen recognition activity, to CAR-T cells chimerizing into specific antibody single-chain variable region (scFv) fragments and costimulatory molecule regions became the mainstream Then, CAR-T cells are clinically recognized as a safe, effective, and continuous immune cell therapy thatkills tumor cells.
The birth of chimeric antigen receptor T cells ( CAR-T cells) is a landmark event in the struggle between humans and tumors
Heart blood vessels
In this retrospective study drug warning, the authors used the Food and Drug Administration Adverse Event Reporting System Board to determine axicabtagen-ciloleucel (referred to as AC) and tisagenlecleucel (referred to as TG) related CPAEs
.
The author evaluated the disproportionate report by the probability of reporting (ROR) and the lower limit of the 95% confidence interval for the information component (IC025>0 is considered significant)
manage
The CAR-T report of 2657 patients was finally confirmed, including 546 CPAEs (20.
5%)
.
In 68.
Compared with the complete database, CAR-T and excessive reporting of tachycardia (n = 74 [2.
Summary of all adverse cardiopulmonary events of CAT-T therapy, AC therapy, and TG therapy
Meanwhile, venous thrombosis thromboembolic events (VTEs) AC only treatment-related (n-28 = [1.
6%], adj.
ROR = 1.
80 [1.
24-2.
62], IC025> 0)
.
Atrial fibrillation (n = 55) is the main tachyarrhythmia , followed by ventricular arrhythmia (n = 14)
Meanwhile, venous thrombosis thromboembolic events (VTEs) AC only treatment-related (n-28 = [1.
In summary, the study found that CAR-T is associated with cardiopulmonary adverse events including tachycardia, cardiomyopathy, pericardial and pleural diseases, and VTEs
references:
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Leave a message here
